Hua Medicine (2552) H1 2026 earnings summary

Executive summary

• Achieved rapid commercialization progress with HuaTangNing, driving a 74% year-over-year revenue increase to RMB378.9 million for H1 2026, supported by a 73% increase in sales volume to 3,055,000 packs and expanded commercialization team.

• Gross profit rose 99% year-over-year to RMB234.3 million, with gross margin improving to 61.8% from 54.2% due to expanded production scale and efficiency.

• Net loss narrowed significantly to RMB30.2 million, excluding the prior year’s one-off Bayer contract termination gain, reflecting improved operational efficiency.

• Cash balances remained strong at RMB1,072.9 million as of June 30, 2026, supporting ongoing R&D and commercialization initiatives.

• Patent life for dorzagliatin extended to April 2034, with new product launches in Hong Kong and Macao and expansion plans for Southeast Asia.

Financial highlights

• Revenue rose 74% year-over-year to RMB378.9 million, driven by a 73% increase in HuaTangNing sales volume.

• Gross profit increased 99% to RMB234.3 million; gross margin improved by 7.6 percentage points to 61.8%.

• Selling expenses rose 98% to RMB126.9 million, mainly due to team expansion and increased marketing activities; selling expense ratio at 33.5%.

• R&D expenses were RMB66.8 million, up slightly from RMB65.8 million, reflecting ongoing clinical trials and post-marketing studies.

• Net loss for the period was RMB30.2 million, with adjusted loss narrowing by RMB29.4 million year-over-year (excluding 2025's one-off gain).

Outlook and guidance

• Targeting continued strong sales growth and geographic expansion, leveraging AI tools and commercialization capabilities.

• Expecting to achieve profitability in 2027, with ongoing investment in pipeline expansion and new indications for dorzagliatin.

• U.S. Phase Ib MAD trial for second-generation GKA to complete in H2 2026, with plans for global partnerships.

• Employee incentive-linked revenue targets set at RMB900 million for 2026.

• NDA submission for dorzagliatin/metformin FDC planned for 2027.